Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 Daily cadence·136 episodes·Last published 2w ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 16 epsHost
Recent guests
Recent episodes
CEO Lavell Malloy on Brag House's (Nasdaq: TBH) Blockchain Sports Platform & Athlete Tokenization
Jun 9, 2026
6m 14s
CEO James Foster on Virax Biolabs' (VRAX) Long COVID Diagnostic & US Market Entry
May 25, 2026
8m 34s
Jeremy Schwartz CIO of WisdomTree ($WT): $165B AUM, Mega Trends & Why WT Is a Secular Growth Stock
May 20, 2026
8m 32s
First Phosphate (FRSPF) CEO on Agnico's $94M Bet Leaves Only 2 Independents Standing
May 12, 2026
8m 17s
Anixa Biosciences (ANIX): CEO on Breast Cancer Vaccine, Phase 2 Catalyst & Ovarian Cancer CAR-T Data
May 11, 2026
9m 15s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/9/26 | CEO Lavell Malloy on Brag House's (Nasdaq: TBH) Blockchain Sports Platform & Athlete Tokenization✨ | blockchainsports finance+5 | Lavell Juan Malloy II | Brag HouseHouse of Doge+2 | Gen Zglobal sports economy+2 | Brag Houseblockchain+8 | — | 6m 14s | |
| 5/25/26 | CEO James Foster on Virax Biolabs' (VRAX) Long COVID Diagnostic & US Market Entry✨ | Long COVIDDiagnostics+3 | James Foster | ViraxImmune™Virax Biolabs Group Ltd. | U.S. | Long COVIDVirax Biolabs+5 | RedChip | 8m 34s | |
| 5/20/26 | Jeremy Schwartz CIO of WisdomTree ($WT): $165B AUM, Mega Trends & Why WT Is a Secular Growth Stock✨ | asset managementinvesting+4 | Jeremy Schwartz | $5B European defense ETFU.S. minerals ETF+4 | EuropeU.S. | WisdomTreeETF+7 | — | 8m 32s | |
| 5/12/26 | First Phosphate (FRSPF) CEO on Agnico's $94M Bet Leaves Only 2 Independents Standing✨ | phosphate acquisitionLFP battery supply chain+4 | John Passalacqua | LFP batteriesphosphate+4 | North AmericaFox River Resources | First PhosphateAgnico Mines+6 | RedChip | 8m 17s | |
| 5/11/26 | Anixa Biosciences (ANIX): CEO on Breast Cancer Vaccine, Phase 2 Catalyst & Ovarian Cancer CAR-T Data✨ | oncologycancer vaccines+4 | Dr. Amit Kumar | breast cancer vaccineovarian cancer CAR-T+4 | United States | Anixa Biosciencesbreast cancer vaccine+4 | — | 9m 15s | |
| 4/28/26 | CEO Brandon Robinson on Horizon Aircraft’s (HOVR) Commercial eVTOL Advantages✨ | eVTOLadvanced air mobility+4 | Brandon Robinson | Cavorite X7New Horizon Aircraft+1 | Horizon Aircraft | HOVRHorizon Aircraft+7 | RedChip Companies | 7m 54s | |
| 4/21/26 | First Phosphate (FRSPF) CEO on $16.7M Non-Dilutive Funding, LFP Batteries, and Why FRSPF Stands Out✨ | non-dilutive fundingLFP battery market+4 | John Passalacqua | LFP batteriesFirst Phosphate+1 | North AmericaEurope | First Phosphatenon-dilutive funding+5 | RedChip | 7m 35s | |
| 4/14/26 | RedChip Highlights Enlivex Therapeutics Ltd. (NASDAQ: ENLV) & Off The Hook Inc. (NYSE American: OTH)✨ | small-cap stocksinvesting+3 | — | Enlivex Therapeutics Ltd.Off The Hook Inc.+1 | — | Enlivex TherapeuticsOff The Hook Inc.+3 | — | 26m 59s | |
| 4/7/26 | SCAP Portfolio Manager Jay Hatfield’s Market Playbook: Fed Cuts, Core PCE, and Small Caps✨ | small-cap investingportfolio construction+4 | Jay Hatfield | InfraCap Small Cap Income FundNYSE: SCAP+2 | — | small capsdividends+5 | — | 10m 46s | |
| 3/31/26 | Enlivex (Nasdaq: ENLV) - FY25 Financial Results Webcast Replay✨ | financial resultsbiotech+3 | — | Allocetra™Enlivex+1 | — | Enlivexfinancial results+5 | RedChip | 24m 40s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 3/24/26 | Enlivex (ENLV) CEO: Two Pillars of Growth, Allocetra Knee OA Catalyst + RAIN Treasury Optionality✨ | biotech executionbalance sheet strategy+4 | Oren Hershkovitz | AllocetraTMEnlivex+1 | Nasdaqknee osteoarthritis | EnlivexAllocetra+6 | — | 8m 46s | |
| 3/17/26 | Off The Hook (NYSE American: OTH) CEO Interview: $145M Revenue Path, AI Boat Platform, Apex Upside✨ | AI technologyboat market+4 | Brian John | Off The HookNYSE American | — | Off The HookAI Boat Platform+7 | RedChip | 12m 33s | |
| 3/10/26 | Comprehensive Healthcare Systems (CMHSF | CHS): CEO Interview on Healthcare SaaS and Pipeline Growth✨ | healthcare technologySaaS+4 | Chris Cosgrove | Comprehensive Healthcare SystemsNovus 360+2 | U.S. | healthcare SaaSclaims adjudication+5 | — | 7m 26s | |
| 3/3/26 | The Metals Company (TMC) CFO Craig Shesky: The NOAA Path, $23.6B NPV, and US Supply Security✨ | critical metalsenvironmental impact+3 | Craig Shesky | polymetallic nodulesThe Metals Company+3 | US | The Metals CompanyCraig Shesky+3 | — | 12m 03s | |
| 2/24/26 | BioVie (Nasdaq: BIVI) CEO Cuong Do on Near Term Catalysts in Parkinson’s, Long COVID, and Ascites✨ | Parkinson'sLong COVID+5 | Cuong Do | bezisterimBIV201+1 | Nasdaq | BioVieBIVI+5 | RedChip | 10m 20s | |
| 2/17/26 | First Phosphate CEO John Passalacqua: Building a North American LFP Battery Supply Chain (FRSPF)✨ | LFP batteriesNorth American supply chain+3 | John Passalacqua | First PhosphateOTCQX+2 | Quebec | LFPbattery supply chain+3 | RedChip | 6m 45s | |
| 11/25/25 | BullFrog AI CEO Vin Singh: Using AI to Transform Drug Discovery and Cut Development Costs | In this exclusive interview, BullFrog AI (Nasdaq: BFRG) CEO Vin Singh discusses how the company’s proprietary bfLEAP™ AI platform and BullFrog Data Networks™ are redefining the economics of drug discovery and development.💡 Key Highlights from the Interview:• Exclusive Data Access: Collaborations with the Lieber Institute for Brain Development and J. Craig Venter Institute provide unmatched datasets driving new discoveries in neuropsychiatric and oncology research.• Commercial Traction: Strategic partnership with Sygnature Discovery enables global sales of BullFrog Data Networks, with up to $30M in projected revenue over 3 years.• Operational Efficiency: Lean model burning just $6M annually while advancing multiple revenue-generating programs.• Clinical Validation: Recent success in a Phase 3 oncology study with Eleison Pharmaceuticals demonstrates the power of BullFrog AI’s technology in optimizing clinical trials.• bfPREP™ Launch: New data preparation module accelerates clinical trial readiness by transforming unstructured data into AI-ready formats in days.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Bullfrog AI is a client of RedChip. To learn more about BFRG and to read our full disclosure, visit: BFRGinfo.com.#BFRG #BiotechStocks #AI #DrugDiscovery #ClinicalTrials #Investing #HealthcareInnovation #SmallCapStocks #AIinBiotech | — | ||||||
| 8/26/25 | PhoenixEV CEO John Walsh Interview: 2025 Goals, $200M Backlog and Transit Growth | Phoenix Motor (OTC: PEVMD) is a pioneer and emerging leader in the electric vehicle (“EV”) industry, designing, building, and integrating electric drive systems and manufacturing heavy-duty transit buses and medium- and light- duty commercial EVs. Phoenix operates two primary brands, PhoenixEV, focused on commercial products including heavy and medium duty EVs (transit buses, shuttle buses, school buses and delivery trucks, among others) and EdisonFuture, which intends to serve international markets, particularly Latin America and Caribbeans region.Phoenix is capitalizing on a robust market opportunity backed by significant federal and state regulatory mandates. With a commanding market share in the transit bus segment and a strategic presence in medium-duty vehicles, Phoenix has established a competitive edge through superior product quality and total cost of ownership. The Company has a base of high-profile customers and boasts a strong order backlog, evidencing substantial market demand, with contracted orders and letters of intent for approximately 250+ units representing $200M in potential revenue. Learn more at phoenixev.ai.PhoenixEV is a client of RedChip. Visit www.redchip.com/stocks/PEVMD to learn more. | — | ||||||
| 8/12/25 | Aptevo Therapeutics: Inside a Top-Tier Oncology Pipeline with COO Jeff Lamothe | Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies through its proprietary bispecific antibody platforms, ADAPTIR® and ADAPTIR-FLEX®. The company is advancing a diverse pipeline that includes both clinical and preclinical candidates designed to harness the immune system to target hematologic and solid tumors with greater precision and safety. With a focus on innovation, Aptevo is leveraging modular antibody engineering to address areas of high unmet medical need and capture opportunities across multi-billion-dollar oncology markets.Aptevo Therapeutics is a client of RedChip. Visit APVOinfo.com to learn more. | — | ||||||
| 6/17/25 | Enlivex CEO on Revolutionizing Osteoarthritis Therapy with Allocetra™ | Investor Deep Dive | Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Osteoarthritis and many other diseases reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life-threatening and debilitating “unmet medical needs”.Enlivex Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/enlv to learn more. | — | ||||||
| 6/10/25 | Inside 60 Degrees Pharma: CEO Geoffrey Dow on Fighting Infectious Diseases & Driving Growth | 60 Degrees Pharmaceuticals (Nasdaq: SXTP) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.Visit RedChip.com to learn more. | — | ||||||
| 6/3/25 | Uranium & Lithium Boom: Foremost Clean Energy CEO on the Future of North America's Supply | Foremost Clean Energy Ltd. (Nasdaq: FMST) (CSE: FAT) (WKN: A3DCC8) is a rapidly growing North American uranium and lithium exploration company. The Company holds an option to earn up to a 70% interest in 10 prospective uranium properties (with the exception of the Hatchet Lake, where Foremost is able to earn up to 51%), spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan. As the demand for carbon-free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy. Foremost's uranium projects are at different stages of exploration, from grassroots to those with significant historical exploration and drill-ready targets. The Company's mission is to make significant discoveries alongside and in collaboration with Denison through systematic and disciplined exploration programs.Foremost Clean Energy is a client of RedChip. Visit www.redchip.com/stocks/FMST to learn more. | — | ||||||
| 5/27/25 | FatPipe (Nasdaq: FATN) CEO Talks Profitability, Patented Tech & Global Growth Strategy | FatPipe, Inc. (Nasdaq: FATN) is a pioneer in secure, software-defined networking technologies that simplify and fortify enterprise connectivity. The company develops and markets enterprise-class software solutions—including Software-Defined Wide Area Networking (SD-WAN), Secure Access Service Edge (SASE), and Network Monitoring Services (NMS)—that enable customers to unify, secure, and optimize their digital infrastructure across cloud, hybrid, and on-premise environments.FatPipe serves over 2,500 end-user customers worldwide across sectors such as government, healthcare, finance, education, and retail, with its largest customer bases in the U.S. and India. The company’s patented technology allows for intelligent traffic failover, enhanced security, simplified network management, and deep observability—all delivered through a flexible, subscription-based model. For the fiscal year ended March 31, 2024, FatPipe generated $17.9 million in revenue and $4.4 million in net income—reflecting a strong 24.4% net margin.FatPipe is a client of RedChip. Visit RedChip.com to learn more. | — | ||||||
| 5/20/25 | BioVie CEO Cuong Do on Alzheimer’s Breakthroughs, Liver Disease Pipeline & What’s Ahead | BioVie (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.BioVie is a client of RedChip. Visit RedChip.com to learn more. | — | ||||||
| 5/13/25 | Liberty Star Minerals: Leadership Breaks Down High-Grade Gold & Copper Potential in Arizona | Liberty Star Minerals (OTCQB: LBSR) is a U.S.-based mineral exploration company focused on advancing high-potential copper and gold projects in Arizona’s premier mining districts. The company’s flagship assets include the Red Rock Canyon Gold Project, a rapidly emerging high-grade epithermal gold discovery, and the Hay Mountain Project, a large-scale copper-gold porphyry target with confirmed mineralization. With recent bonanza-grade gold assays at Red Rock Canyon and first-ever drilling validating Hay Mountain’s porphyry potential, Liberty Star is strategically positioned for significant value creation. The company is actively seeking a joint venture partnership to accelerate development while leveraging strong exploration results and a favorable commodities market.Visit www.redchip.com/stocks/lbsr to learn more. | — | ||||||
Showing 25 of 42
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.